References
- Sandler RS. Epidemiology of inflammatory bowel disease. In: Targan SR, Shanahan F, eds. Inflammatory bowel disease: from bench to bedside. Baltimore: Williams & Wilkins, 1994:5–30
- Fanner RG, Easley KA, Rankin GB. Clinical patterns, natural history, and progression of ulcerative colitis: a long-term follow-up of 1116 patients. Dig Dis Sci 1993; 38(6):1137–46
- Podolsky DK. Inflammatory bowel disease: part 1. N Engl J Med 1991; 325(13): 928–37
- Modigliani R. Endoscopic management of inflammatory bowel disease. Am J Gastroenterol 1994; 89(8 Suppl):53–65S
- Truelove SC, Witts LJ. Cortisone in ulcerative colitis. BMJ 1955; 2(Oct 29):1041–8
- Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 1976; 55(5):401–12
- Lennard-Jones JE, Cooper GW, Newell AC, et al. Observations on idiopathic proctitis. Gut 1962; 3:201–6
- Rao SS, Holdsworth CD, Read NW. Symptoms and stool patterns in patients with ulcerative colitis. Gut 1988; 29(3): 342–5
- Korkis AM, McDougall CJ. Rectal bleeding in patients less than 50 years of age. Dig Dis Sci 1995; 40(7):1520–3
- Podolsky DK. Inflammatory bowel disease: part 2. N Engl J Med 1991; 325(14): 1008–16
- Hanauer SB, Stathopoulos G. Risk- benefit assessment of drugs used in the treatment of inflammatory bowel disease. Drug Saf 1991; 6(3):192–219
- Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993; 118(7):540–9
- Leino R, Liippo K, Ekfors T. Sulphasalazine-induced reversible hypersensitivity pneumonitis and fatal fibrosing alveolitis: report of two cases. J Intern Med 1991; 229(6):553–6
- Hanauer SB. Inflammatory bowel disease. N Engl J Med 1996; 334(13):841–8
- Binder SC, Patterson JF, Glotzer DJ. Toxic megacolon in ulcerative colitis. Gastroenterology 1974; 66(5):909–15
- Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305(6844):20–2
- Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330(26):1841–5
- Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110(5):353–6
- Mesalamine Study Group. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis: a randomized, placebo-controlled trial. Ann Intern Med 1996; 124(2):204–11
- Pullan RD, Rhodes J, Ganesh S, et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994; 330(12):811–5
- Stenson WF, Cort D, Rodgers J, et al. Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med 1992; 116(8):609–14
- Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997; 112(2):594–642
- Provenzale D, Kowdley KV, Arora S, et al. Prophylactic colectomy or surveillance for chronic ulcerative colitis? A decision analysis. Gastroenterology 1995; 109(4):1188–96